Table 2 Combination therapy.
From: PD-L1 degradation pathway and immunotherapy for cancer
Degradation by | Regulatory signal | Therapy | Cancer types | Reference |
|---|---|---|---|---|
Proteasome | EGFR/GSK3β/β-TrCP | Gefitinib + anti-PD-1 | Colon cancer, TNBC | |
Proteasome | NFκB/CSN5 | Curcumin + anti-CTLA4 | TNBC, colon cancer, melanoma | |
Proteasome | AMPK | Metformin + CTLA4 | Breast cancer, lung cancer | |
Proteasome | EMT/β-catenin/STT3 | Etoposide + anti-Tim-3 | Colon cancer, TNBC | |
Lysosome | EGFR/B3GNT3 | STM108-MMAE conjugate | TNBC | |
Lysosome | CMTM6 | H1A + cisplatin | Breast cancer, colon cancer | |
Proteasome | CDK4/6/ cullin3SPOP | Palbociclib + anti-PD-1 | Colon cancer |
